Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Considerations for treatment sequencing in B-ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 615
Rating:

Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany

Prof Nicola Gökbuget speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the considerations for treatment sequencing in patients with B-cell acute lymphoblastic leukaemia (B-ALL) when treated with immunotherapy.

She describes the various immunotherapeutic options that are available for this disease type, including blinatumomab and inotuzumab - which both lead to better response rates compared to standard chemotherapy and should be the treatment of choice for early relapse/refractory patients.

However, Prof Gökbuget states that for patients who relapse later, there is currently a lack of data for both agents.

She discusses the challenge of choosing between blinatumomab and inotuzumab and which patient populations will benefit the most.

 

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation